Prostate Cancer Specific RNAs Identified in Urine and Tissue
By LabMedica International staff writers Posted on 27 Oct 2014 |
Researchers have discovered a set of potential-biomarker RNAs that may pave the way to a more reliable prostate cancer (PrCa) screening assay.
A team led by Ranjan J. Perera, PhD, associate professor and scientific director of Analytical Genomics and Bioinformatics at the Lake Nona (Orlando, FA, USA) campus of the Sanford-Burnham Medical Research Institute (Orlando, FA and La Jolla, CA, USA) has identified a set of RNA molecules that are detectable in tissue samples and urine of PrCa patients but not in normal healthy individuals. The study sets the stage for development of more sensitive and specific noninvasive tests for PrCa than those currently available, which could result in fewer unnecessary biopsies and less treatment-related morbidity.
Since most men with PrCa have indolent (nonaggressive) disease for which conservative therapy or surveillance is appropriate, the challenge is not only PrCa diagnosis, but also how to distinguish between patients who would benefit from surgical or other aggressive treatment from those who would not. "While elevated PSA can be an alert to a lethal cancer, it can also detect less aggressive cancers that may never do any harm," said Vipul Patel, MD, medical director of the Global Robotics Institute at Florida Hospital in Orlando (USA), "Moreover, only 25% of men with raised PSA levels that have a biopsy actually have PrCa. PrCa needs to be screened for; we just need to find a better marker."
The team identified a group of long noncoding RNAs (lncRNAs) that may serve as better prognostic PrCa markers. Until recently lncRNAs were dismissed as irrelevant, but are now thought to regulate normal cellular development and are increasingly reported as contributing to various diseases, including cancer. "We have identified a set of lncRNAs that appear to have an important role in PrCa diagnostics," said Prof. Perera, "The findings advance our understanding of the role of lncRNAs in cancer biology and, importantly, broaden the opportunity to use lncRNAs as biomarkers."
The study profiled the lncRNAs in 3 distinct groups: (1) human PrCa cell lines and normal prostate epithelial cells; (2) prostate adenocarcinoma tissue samples and matched normal tissue samples; and (3) urine samples from patients with PrCa or benign prostate hyperplasia, and normal healthy individuals. In each case, the lncRNAs were elevated in PrCa patient samples—but not in patients with benign prostate hyperplasia or normal healthy individuals.
One advantage of lncRNAs is that they can be detected in urine, more easily available than blood. One lncRNA, PCA3, was recently commercialized in a urine test to identify which men suspected of having PrCa should undergo repeat prostate biopsy. However, discrepancies exist between PCA3 levels and clinicopathologic features. In the current study, PCA3 was detected in some but not all samples, suggesting that reliance on a single biomarker may be insufficient for PrCa detection.
"There is a tremendous unmet clinical need for better noninvasive screening tools for early detection of PrCa to reduce the overtreatment and morbidity of this disease," added Dr. Patel, "Our findings represent a promising approach to meet this demand."
The study, by Lee B, Mazar J, et al., was published October 2014, online ahead of print, in the Journal of Molecular Diagnostics, of the Association for Molecular Pathology (AMP).
Related Links:
Sanford-Burnham Medical Research Institute
A team led by Ranjan J. Perera, PhD, associate professor and scientific director of Analytical Genomics and Bioinformatics at the Lake Nona (Orlando, FA, USA) campus of the Sanford-Burnham Medical Research Institute (Orlando, FA and La Jolla, CA, USA) has identified a set of RNA molecules that are detectable in tissue samples and urine of PrCa patients but not in normal healthy individuals. The study sets the stage for development of more sensitive and specific noninvasive tests for PrCa than those currently available, which could result in fewer unnecessary biopsies and less treatment-related morbidity.
Since most men with PrCa have indolent (nonaggressive) disease for which conservative therapy or surveillance is appropriate, the challenge is not only PrCa diagnosis, but also how to distinguish between patients who would benefit from surgical or other aggressive treatment from those who would not. "While elevated PSA can be an alert to a lethal cancer, it can also detect less aggressive cancers that may never do any harm," said Vipul Patel, MD, medical director of the Global Robotics Institute at Florida Hospital in Orlando (USA), "Moreover, only 25% of men with raised PSA levels that have a biopsy actually have PrCa. PrCa needs to be screened for; we just need to find a better marker."
The team identified a group of long noncoding RNAs (lncRNAs) that may serve as better prognostic PrCa markers. Until recently lncRNAs were dismissed as irrelevant, but are now thought to regulate normal cellular development and are increasingly reported as contributing to various diseases, including cancer. "We have identified a set of lncRNAs that appear to have an important role in PrCa diagnostics," said Prof. Perera, "The findings advance our understanding of the role of lncRNAs in cancer biology and, importantly, broaden the opportunity to use lncRNAs as biomarkers."
The study profiled the lncRNAs in 3 distinct groups: (1) human PrCa cell lines and normal prostate epithelial cells; (2) prostate adenocarcinoma tissue samples and matched normal tissue samples; and (3) urine samples from patients with PrCa or benign prostate hyperplasia, and normal healthy individuals. In each case, the lncRNAs were elevated in PrCa patient samples—but not in patients with benign prostate hyperplasia or normal healthy individuals.
One advantage of lncRNAs is that they can be detected in urine, more easily available than blood. One lncRNA, PCA3, was recently commercialized in a urine test to identify which men suspected of having PrCa should undergo repeat prostate biopsy. However, discrepancies exist between PCA3 levels and clinicopathologic features. In the current study, PCA3 was detected in some but not all samples, suggesting that reliance on a single biomarker may be insufficient for PrCa detection.
"There is a tremendous unmet clinical need for better noninvasive screening tools for early detection of PrCa to reduce the overtreatment and morbidity of this disease," added Dr. Patel, "Our findings represent a promising approach to meet this demand."
The study, by Lee B, Mazar J, et al., was published October 2014, online ahead of print, in the Journal of Molecular Diagnostics, of the Association for Molecular Pathology (AMP).
Related Links:
Sanford-Burnham Medical Research Institute
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans